

VITREO-RETINA SOCIETY OF THE PHILIPPINES



CONSENSUS ON INTRAVITREAL INJECTION TECHNIQUE AMONG INFANTS WITH RETINOPATHY OF PREMATURITY

MARIE JOAN V. LOY, MD
JEFFREY C. LIM, MD

JULY 14, 2020



VRSP Board 2020-2021

Marie Joan V. Loy, MD
President

Ricardo Tobias M. Papa, MD
Vice President

Eleonore B. Iguban, MD
Secretary

Jubaida M. Aquino, MD
Treasurer

Junn R. Pajarillo, MD
Darby E. Santiago, MD
Ronald A. Yutangco, MD
Board Members

Sherman O. Valero, MD
Immediate Past President

ACKNOWLEDGMENT

Pearl M. Tamesis-Villalon, MD
Jubaida M. Aquino, MD
Lyll Karen A. Bigornia-Arriola, MD
Narciso F. Atienza Jr, MD
Jesus Jacinto M. Bautista, MD
Karina Q. De Sagun-Bella, MD
Perfecto R. Cagampang III, MD
Mary Louise G. Calaycay, MD
George Christopher C. Chan, MD
Danilo V. Constantino II, MD
Jose Luis G. De Grano, MD
Fabian Arnel A. De Jesus, MD
Catherine Dianne R. Delfino, MD
Leslie B. Gatchalian, MD
Rory K. Go, MD
Maria Florentina F. Gomez, MD
Redentor Caesar G. Gonzalez, MD
Eleonore B. Iguban, MD
Jose Melvin B. Jimenez IV, MD
John Alfred H. Lim, MD
Ronnie S. Manaysay, MD
Mark Gil J. Marasigan, MD
Jesus F. Marin, MD
Junn R. Pajarillo, MD
Patricia G. Quilendrin, MD
Darby E. Santiago, MD
Angelica B. Cabero-Santos, MD
Farlah Angela S. Sevilla, MD
Bernardo Joaquin P. Tuaño, MD
Christopher Sebastian J. Uy, MD
Ramon R. Valenzuela, MD
Kristine D. Corpus-Velasquez, MD
Ronald A. Yutangco, MD



CONSENSUS ON THE INTRAVITREAL INJECTION TECHNIQUE AMONG INFANTS WITH RETINOPATHY OF PREMATURITY BY THE VITREO-RETINA SOCIETY OF THE PHILIPPINES

Introduction

Retinopathy of prematurity (ROP) is a potentially blinding vasoproliferative disease that may occur in infants born <32 weeks,¹ those born with birth weight of ≤ 1500 g,¹ or those born 32-36 weeks but with unstable clinical course (severe sepsis, blood transfusion within the first 10 days due to anemia, oxygen use especially if without oxygen blender, and high risk infants as assessed by the neonatologist).¹⁻⁷ Management of ROP varies depending on the stage of the disease ranging from observation,^{8,9} laser treatment,⁹ to surgery.¹⁰

Several studies have shown the role of vascular endothelial growth factors (VEGF) in the pathogenesis of ROP.^{11,12} There is growing evidence that intravitreal injection of anti-vascular endothelial growth factors (anti-VEGF) provides favorable outcomes in the management of ROP.^{11,12}

In the BEAT-ROP study (Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of Prematurity), intravitreal bevacizumab showed significant benefit over conventional laser therapy for stage 3+ ROP within zone 1. The study also noted that there was continued vascularization of the peripheral retina after intravitreal bevacizumab, whereas conventional laser therapy destroyed the peripheral retina and caused permanent visual field defects.¹³

In the RAINBOW study (Ranibizumab Versus Laser Therapy for the Treatment of Very Low Birthweight Infants with Retinopathy of Prematurity), premature infants treated with ranibizumab 0.2 mg were twice as likely to achieve clinically significant treatment success compared to infants treated with conventional laser.¹⁴ In September of 2019, 0.2 mg ranibizumab was approved by the European Commission for the management of ROP with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or aggressive posterior ROP (AP-ROP) disease.¹⁵

Intravitreal injection of anti-VEGF is now an acceptable option for the treatment of ROP, however, publications about the intravitreal injection technique among infants are scarce. Considering the anatomic differences between adults and newborns, the Vitreo-Retina Society of the Philippines found the need to create guidelines in the Philippine setting for the performance of intravitreal injections among infants.

- I. All intravitreal injections for ROP should be performed by a member of the Vitreo-Retina Society of the Philippines (VRSP) or the Philippine Society of Pediatric Ophthalmology and Strabismus (PSPOS). A Philippine Board of Ophthalmology (PBO) certified member of the Philippine Academy of Ophthalmology (PAO), who is knowledgeable, skilled, and comfortable in the diagnosis and comprehensive management of retinopathy of prematurity, may inject anti-VEGF agents in infants with ROP if performed under the guidance of a VRSP or PSPOS member. This is an option if no VRSP or PSPOS members are available in the locality.
- II. Clinical Setting of Care
The procedure may be performed in either an operating room, a room designated for intravitreal injections, a neonatal intensive care unit, a nursery, at bedside, or in the clinic as long as the venue for the injection is adequately clean.¹⁶



III. Preprocedural Issues

A. Informed Consent¹⁷

- a. Informed consent forms specific for intravitreal injection and specific for the off-label use of anti-VEGF agents for ROP have to be signed prior to the procedure.
- b. The consent form should include the name of the drug to be injected, the indication for injection, and the potential risks and benefits of the use of anti-VEGF agents and of the procedure itself.
- c. Information must be fully explained to the parents of the infant.

B. Pediatric Clearance

- a. The benefits, risks, and indications of anti-VEGF injections should be carefully considered in premature babies, especially if with systemic comorbidities.
- b. The necessity for a pediatric clearance will be at the discretion of the attending ophthalmologist.

IV. Surgical Site Preparation

- A. Intravitreal injections in infants are intraocular procedures that require adherence to principles of asepsis and sterile technique as for other conventional intraocular surgeries.
- B. There is no robust evidence to support that the instillation of a topical antibiotic eye drops before the intravitreal injection reduces the risk of subsequent intraocular infection.^{18, 19}
- C. The infant's pupil/s may be dilated using a combination of 0.5% tropicamide and 0.5% phenylephrine to start at least 30 minutes before the scheduled time of injection. Excess eye drop should be wiped off immediately from the skin and punctal occlusion with a finger may also be done for 3-4 minutes after instillation of the mydriatic drops to decrease systemic absorption and to minimize possible systemic adverse effects.²⁰
- D. Preoperative disinfection of the periocular skin with 10% povidone-iodine and a minimum exposure time of 3 minutes is suggested.²¹ Aqueous chlorhexidine in minimum amount to avoid chemical skin burn may be used as an alternative in infants with hypersensitivity to povidone iodine. Wipe off any excess solution immediately to prevent skin irritation.²²
- E. The use of a newly opened bottle of topical anesthetic eye drops is advised.
- F. 5% povidone iodine should be applied onto the conjunctival cul-de-sac or lower fornix with a minimum contact time of 30 seconds.²³ Chlorhexidine 0.05% to 0.1% may be flushed on the lashes and lids in infants with hypersensitivity to povidone iodine.²⁴ Wipe off any excess solution immediately to prevent skin irritation.²²
- G. The use of a sterile solid-blade lid speculum is recommended to isolate the lashes from the site of injection.^{16, 25}

V. Injection Procedure


- A. Intravitreal injection is performed under topical anesthesia.
- B. A competent assist is important to gently position and secure the head of the swaddled infant during the injection.²⁶ If the infant is on mechanical ventilation, the arms must be secured and the head be held by the assistant during the injection.
- C. As part of good surgical practice, the donning of sterile surgical gloves¹⁶ and the wearing of a surgical mask²⁷ are advised.
- D. The injection site varies depending on the age of the infant with much care to avoid iatrogenic retinal tears and injury to the globular crystalline lens of the infant.



Intravitreal Injection Site for Retinopathy of Prematurity ²⁸	
Post-Menstrual Age, wks	Distance Posterior to Limbus,* mm
34	1.6 - 2.1
35	1.6 - 2.1
36	1.6 - 2.1
37	1.5 - 2.0
38	1.5 - 2.0
39	1.4 - 1.9
40	1.4 - 1.9
41	1.4 - 1.9
42	1.3 - 1.8
43	1.3 - 1.8
44	1.3 - 1.8
45	1.2 - 1.7
46	1.2 - 1.7
47	1.2 - 1.7
48	1.1 - 1.6

* It was recommend that nasal sclerotomies be 0.25-0.5 mm shorter than the recommended location.

- E. The present recommendation is to inject half of the adult dose (0.625 mg/0.025 ml for bevacizumab,¹³ 0.2 mg/0.025 ml for ranibizumab¹⁴), preferably at the temporal quadrants in a vertical orientation parallel to the visual axis to avoid hitting the lens.²⁹ The optimum dose for injection may change as more studies are published in the future.



- F. Sterile 30-gauge 0.5 inch disposable needle on a 1 cc syringe or, when available, finer and shorter needle on a syringe with smaller capacity may be used for intravitreal injection of anti-VEGF agents. The needle must be inserted just deep enough to penetrate the sclera and enter the vitreous when performing the injection. At most, less than half the length of the



30-gauge needle should be inserted into the eye. It is essential to refrain from inserting the entire length of the needle into the eye to avoid hitting the retina.²⁹ Stabilize the hand by anchoring the middle finger to prevent the needle from going too deep just in case the infant moves. This also provides additional stability to the eyeball and proprioceptive feedback to the surgeon. An appropriately sized cotton applicator or a sterile Flynn scleral depressor may be used to position the globe as needed. If the baby is restless and uncooperative, wait for a few minutes for the infant to settle down or give a pacifier.

- G. When injecting the anti-VEGF agent, avoid injecting with undue intensity that may cause a retinal injury from the jet stream produced by injection.
 - H. After the injection and the needle is withdrawn, the ophthalmologist may apply a sterile cotton applicator to prevent reflux of liquid vitreous.
 - I. Whenever possible, the ophthalmologist should assess lens clarity, central retinal artery and optic nerve perfusion by checking for venous pulsation, and presence of retinal breaks via indirect ophthalmoscopy.
 - J. Anterior chamber paracentesis may be promptly performed in cases that show a sustained rise in intraocular pressure.
 - K. Bilateral same day injections:^{16,25}
 - 1. Each eye should be prepared with povidone-iodine separately.
 - 2. A completely new and different surgical set of lid speculum, instruments, 30-gauge needle and syringe should be utilized.
 - 3. Whenever feasible, separate vials of medication with different lot numbers should be used for each eye. Record the lot numbers in the operative record.
 - L. There is no robust evidence to suggest that the instillation of post-injection antibiotics provides additional benefit in reducing the risk of intraocular infection after intravitreal injections.^{16,30,31}
- VI. Post-Injection Management
- A. Post-injection follow-up is advised within 7 days then monitor the status of ROP as necessary.
 - B. Parents should be instructed to bring the infant sooner for follow-up if with signs of inflammation or infection.

This consensus statement is subject to reevaluation and revision as new evidence-based studies on intravitreal anti-VEGF injections among infants become published and new practice patterns evolve.

REFERENCES:

1. Paulino JAT, et al. Comparison of the detection rates for retinopathy of prematurity of the 2013 Philippine Academy of Ophthalmology Revised Philippine Guidelines and the 2005 Philippine Academy of Ophthalmology-Philippine Pediatric Society Guidelines for ROP Screening in the Philippine General Hospital: A 5-year review. Presented at the Philippine Academy of Ophthalmology (PAO) Fellows' Research Competition, PAO Annual Meeting 2019. Unpublished.
2. Fierson WM. Screening examination of premature infants for retinopathy of prematurity. *Pediatrics*. December 2018, 142(6).



3. Gilbert C, et al. Characteristics of infants with severe retinopathy of prematurity in countries with low, moderate, and high levels of development: Implications on screening programs. *Pediatrics*. 2005;115(5): e518-e525.
4. Lee J, Dammann O. Perinatal infection, inflammation, and retinopathy of prematurity. *Semin Fetal Neonatal Med*. 2012;17(1):26-29.
5. Lust C, Vesoulis C, Jackups R, et al. Early red cell transfusion is associated with severe retinopathy of prematurity. *Perinatol*. 2019 March;39(3):393–400.
6. Philippine Society of Newborn Medicine Manual of Neonatal Resuscitation (NRPh+, 2018). Philippine Society of Newborn Medicine, Quezon City, Philippines.
7. WHO Library Cataloguing-in-Publication Data. WHO recommendations to improve preterm birth outcomes. Contents: Appendix: WHO recommendations on interventions to improve preterm birth outcomes: evidence base. 1. Premature Birth prevention and control. 2. Infant, Premature 3. Infant Mortality - prevention and control. 4. Prenatal Care. 5. Infant Care. 6. Guideline. I. World Health Organisation. ISBN 978924150898 8 (NLM Classification : WQ 330)
8. Cryotherapy for ROP Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity: Three-month outcome. *Arch Ophthalmol* 1990; 108: 195-204.
9. Early Treatment for ROP Cooperative Group. Revised indications for the treatment of ROP: Results of the early treatment for ROP randomized trial. *Arch Ophthalmol*. 2003; 121:1684-94.
10. Hartnett ME, Maguluri S, et al. Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. *Retina*. 2004;24(5):753-757.
11. Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity. *New England Journal of Medicine*. 2013;368(12):1162-1163.
12. Chen J, Smith LE. Retinopathy of prematurity. *Angiogenesis*. 2007;10(2):133-140.
13. Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. *N Engl J Med*. 2011; 364: 603–15.
14. Stahl A, Lepore D, Fielder, A, et al. Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial. *Lancet*. 2019. [http://dx.doi.org/10.1016/S0140-6736\(19\)31344-3](http://dx.doi.org/10.1016/S0140-6736(19)31344-3)
15. The Pharma Letter. Up to date news for the Pharmaceutical and Biotechnology industries. September 06, 2019: <https://www.thepharmaletter.com/in-brief/brief-new-eu-approval-for-novartis-lucentis> (accessed June 28, 2020).
16. Grzybowski A, Told R, Sacu S, et al. 2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations. *Ophthalmologica*. 2018. doi: 10.1159/000486145
17. Ophthalmic Mutual Insurance Company. Consent forms: <http://www.omic.com/wp-content/uploads/2016/04/Anti-VEGF-for-ROP.docx> (accessed June 28, 2020).
18. Hunyor AP, Merani R, Darbar A, Korobelnik JF, Lanzetta P, Okada AA. Topical antibiotics and intravitreal injections. *Acta Ophthalmol*. 2018;96(5):435-441. doi:10.1111/aos.13417
19. Moss JM, Sanislo SR, Ta CN. A prospective randomized evaluation of topical gatifloxacin on conjunctival flora in patients undergoing intravitreal injections. *Ophthalmology*. 2009;116(8):1498-1501. doi:10.1016/j.ophtha.2009.02.024
20. Myers TM, Wallace DK, Johnson SM. Ophthalmic medications in pediatric patients. *Comprehensive Ophthalmology Update*. 2005;6(2):85-101.
21. Barry P, Behrens-Baumann W, Pleyer U, Seal D. ESCRS guidelines on prevention, investigation, and management of postoperative endophthalmitis. Version 2. August 2007.



22. UK Medicines and Healthcare Products Regulatory Agency. (2014b). *Chlorhexidine solutions: Risk of chemical burn injury to skin in premature infants*. <http://www.mhra.gov.uk/safetyinformation/drugsafetyupdate/con428307> (accessed July 10, 2020).
23. Friedman DA, Mason JO 3rd, Emond T, McGwin G Jr. Povidone-iodine contact time and lid speculum use during intravitreal injection. *Retina*. 2013;33(5):975-981. doi:10.1097/IAE.0b013e3182877585
24. Merani R, McPherson ZE, Lucki AP, et al. Aqueous chlorhexidine for intravitreal injection antisepsis. *Ophthalmology*. 2016;123(12):2588-2594.
25. Lau PET, Jenkins KS, Layton CJ. Current evidence for the prevention of endophthalmitis in anti-VEGF intravitreal injections. *Journal of Ophthalmology*. 2018. <https://doi.org/10.1155/2018/8567912>
26. Hered RW, Gyland EA. The retinopathy of prematurity screening examination: Ensuring a safe and efficient examination while minimizing infant discomfort. *Neonatal Network* May/June 2010;29(3):143-151.
27. Doshi RR, Leng T, Fung AE. Reducing oral flora contamination of intravitreal injections with face mask or silence. *Retina*. 2012;32:473-6.
28. Wright LM, Harper A, Chang E. Management of infantile and childhood retinopathies: Optimized pediatric pars plana vitrectomy sclerotomy nomogram. *Ophthalmology Retina*. 2018. <https://doi.org/10.1016/j.oret.2018.06.008>
29. Williams GA. Technique for infant intravitreal injection in treatment of retinopathy of prematurity. *Retina, The Journal of Retinal and Vitreous Diseases*. 2017;37(11):2188-2190.
30. Bhavsar AR, Stockdale CR, Ferris FL 3rd, et al. Update on risk of endophthalmitis after intravitreal drug injections and potential impact of elimination of topical antibiotics. *Arch Ophthalmol*. 2012;130(6):809-810. doi:10.1001/archophthalmol.2012.227
31. Cheung CS, Wong AW, Lui A, Kertes PJ, Devenyi RG, Lam WC. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections. *Ophthalmology*. 2012;119(8):1609-1614. doi:10.1016/j.optha.2012.02.014